Method and composition for producing a cellular allogeneic vaccine

Abstract

The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

1 .- 20 . (canceled) 
     
     
         21 . A method for inducing an antigen-specific immune response to treat cancer in a subject, said method comprising administering an effective amount of a cellular allogeneic fully MHC-incompatible immunogenic composition to a subject in need thereof, wherein said allogeneic fully MHC-incompatible immunogenic composition is a fully MHC-incompatible monocyte-derived dendritic cell transfected with a gene coding for a soluble cancer antigen. 
     
     
         22 . The method according to  claim 21 , wherein the monocyte-derived dendritic cell is transected with more than gene, said genes coding for different cancer antigens. 
     
     
         23 . The method according to  claim 21 , wherein the gene codes for a cancer antigen from a breast tumor cell. 
     
     
         24 . The method according to  claim 21 , wherein the gene codes for a cancer antigen from a prostate tumor cell. 
     
     
         25 . The method according to  claim 21 , wherein the gene codes for a cancer antigen of allogeneic origin. 
     
     
         26 . The method according to  claim 21 , wherein the sialic acid has been removed from the surface of said monocyte-derived dendritic cell. 
     
     
         27 . A method for inducing an antigen-specific immune response in a subject, said method comprising administering an effective amount of a cellular allogeneic fully MHC-incompatible immunogenic composition to a subject in need thereof, wherein said allogeneic fully MHC-incompatible immunogenic composition is a fully MHC-incompatible monocyte-derived dendritic cell transfected with a gene coding for a soluble cancer antigen. 
     
     
         28 . The method according to  claim 27 , wherein the monocyte-derived dendritic cell is transected with more than gene, said genes coding for different cancer antigens. 
     
     
         29 . The method according to  claim 27 , wherein the gene codes for a cancer antigen from a breast tumor cell. 
     
     
         30 . The method according to  claim 27 , wherein the gene codes for a cancer antigen from a prostate tumor cell. 
     
     
         31 . The method according to  claim 27 , wherein the gene codes for a cancer antigen of allogeneic origin. 
     
     
         32 . The method according to  claim 27 , wherein the sialic acid has been removed from the surface of said monocyte-derived dendritic cell. 
     
     
         33 . A method for treating cancer in a subject, said method comprising administering an effective amount of a cellular allogeneic fully MHC-incompatible immunogenic composition to a subject in need thereof, wherein said allogeneic fully MHC-incompatible immunogenic composition comprises an effective amount of a fully MHC-incompatible monocyte-derived dendritic cell transfected with a gene coding for a soluble cancer antigen. 
     
     
         34 . The method according to  claim 33 , wherein the monocyte-derived dendritic cell is transected with more than gene, said genes coding for different cancer antigens. 
     
     
         35 . The method according to  claim 33 , wherein the gene codes for a cancer antigen of allogeneic origin. 
     
     
         36 . The method according to  claim 33 , wherein the gene codes for a cancer antigen from a breast tumor cell. 
     
     
         37 . The method according to  claim 33 , wherein the gene codes for a cancer antigen from a prostate tumor cell. 
     
     
         38 . The method according to  claim 33 , wherein the sialic acid has been removed from the surface of said monocyte-derived dendritic cell.